72755-13-6

Basic information

• Product Name: Carbamic acid, (3-fluorophenyl)-, methyl ester
• Synonyms: (3-fluorophenyl)carbamic acid methyl ester;(3-Fluoro-phenyl)-carbamic acid methyl ester;methyl (3-fluorophenyl)carbamate;methyl N-(3-fluorophenyl)carbamate
• CAS NO: 72755-13-6
• Molecular Formula: C8H8FNO2
• Molecular Weight: 169.155
• Mol File: 72755-13-6.mol
• Article Data: 12

Chemical Properties

• Melting Point: 64.2 - 67.2 °C
• CAS DataBase Reference: Carbamic acid, (3-fluorophenyl)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-fluorophenyl)-, methyl ester(72755-13-6)
• EPA Substance Registry System: Carbamic acid, (3-fluorophenyl)-, methyl ester(72755-13-6)

Safety Data

• Hazardous Substances Data: 72755-13-6(Hazardous Substances Data)

Upstream product

• 372-19-0 meta-fluoroaniline 
• 79-22-1 methyl chloroformate 
• 67-56-1 methanol 
• 455-37-8 3-fluorobenzamide 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 396076-65-6 (4-bromo-3-fluoro-phenyl)-carbamic acid methyl ester 

Relevant articles and documents

Design and synthesis of biaryloxazolidinone derivatives containing a rhodanine or thiohydantoin moiety as novel antibacterial agents against Gram-positive bacteria

Novel biaryloxazolidinone derivatives containing a rhodanine or thiohydantoin moiety were designed, synthesized and evaluated for their antibacterial activity. The key compounds 7 and 9 were synthesized by the knoevenagel condensation of intermediate aldehyde 5 with rhodanine derivatives 6a?6b. The preliminary study showed that compounds 7, 9 and 10e exhibited potent antibacterial activity with MIC values of 0.125 μg/mL against S. aureus, MRSA, MSSA, LREF and VRE pathogens, using linezolid and radezolid as the positive controls. The most promising compound 10e exhibited potent antibacterial activity against tested clinical isolates of MRSA, MSSA, VRE and LREF with MIC values in the range of 0.125–0.5 μg/mL, and the potency of 10e against clinical isolates of LREF was 64-fold higher than that of linezolid. Moreover, compound 10e was non-cytotoxic with an IC50 value of 91.04 μM against HepG2 cell. Together, compound 10e might serve as a novel antibacterial agent for further investigation.

Synthesis and antibacterial activity evaluation of novel biaryloxazolidinone analogues containing a hydrazone moiety as promising antibacterial agents

A series of linezolid analogues containing a hydrazone moiety were designed, synthesized and evaluated for their antibacterial activity. Most compounds exhibited more potent antibacterial activity against S.aureus, MRSA, MSSA, LREF and VRE pathogens as compared with linezolid and radezolid. Compounds 9a, 9c, 9f, 9g, 10m and 10t were more potent against tested clinical isolates of MRSA, MSSA, VRE and LREF as compared to linezolid. Compound 9a exhibited comparable activity with linezolid against human MAO-A for safety evaluation and showed moderate metabolism in human liver microsome. The most promising compound 9a showed remarkable antibacterial activity against S.aureus, MRSA, MSSA, LREF and VRE pathogens with MIC value of 0.0675 mg/mL, respectively, which was 15- to 30-fold more potent than linezolid.

Preparation method of biaryl oxazolidone intermediate

The invention relates to a preparation method of a biaryl oxazolidone intermediate (5S)-N-[[3-(3-fluoro-4-iodophenyl)-2-oxooxazolidine-5-ol]methyl]acetamine (I). According to the method, the intermediate is prepared with m-fluoroaniline as an initial raw material through amino protection, iodination and cyclization sequentially. Compared with a reported preparation method of the biaryl oxazolidone intermediate, the method adopts a short route, increases the yield, greatly reduces the cost and is more suitable for industrial production.